Prognostic and Clinicopathological Significance of Ubiquitin-specific Protease 22 Overexpression in Cancers: Evidence from a Meta-analysis

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2017 Dec 5

PMID 29200868

Citations 3

Authors

Ning Ao

Liang Wang

Yuqin Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: This meta-analysis study aimed to reveal the prognostic relevance of ubiquitin-specific protease 22 (USP22) expression in patients with cancers.

Methods: PubMed, Embase, and the Cochrane Library electronic databases were searched for relevant studies published up to April 2017. The prognostic value of USP22 expression was evaluated by hazard ratio with 95% confidence intervals (CIs). Relative risk (RR) with 95% CIs assessed the effects of USP22 expression on clinicopathological parameters. A total of 16 studies of 2,233 Chinese patients were included in the final meta-analysis.

Results: A significant association was found between USP22 overexpression and survival in patients with cancers. The pooled RR indicated that USP22 overexpression was related to histological grade, advanced tumor-node-metastasis stage, positive lymph node metastasis, and distant metastasis.

Conclusion: This meta-analysis demonstrated that USP22 could be a novel biomarker for predicting prognosis in patients with cancers in the Chinese population.

Citing Articles

Evaluation of USP22 and Ki-67 expression in oral squamous cell carcinoma: An immunohistochemical study.

Apoorva C, Ananthaneni A, Kumar A, Guduru V, Puneeth H J Oral Maxillofac Pathol. 2024; 27(4):679-684.

PMID: 38304522 PMC: 10829464. DOI: 10.4103/jomfp.jomfp_262_23.

The Relationship between Oxidative Status and Radioiodine Treatment Qualification among Papillary Thyroid Cancer Patients.

Buczynska A, Sidorkiewicz I, Kosciuszko M, Adamska A, Siewko K, Dzieciol J Cancers (Basel). 2023; 15(9).

PMID: 37173902 PMC: 10177082. DOI: 10.3390/cancers15092436.

USP22 promotes proliferation in renal cell carcinoma by stabilizing survivin.

Lin Y, Zhong H, Sun B, Peng Y, Lu F, Chen M Oncol Lett. 2020; 20(5):246.

PMID: 32973959 PMC: 7509511. DOI: 10.3892/ol.2020.12108.

References

Ao N, Liu Y, Feng H, Bian X, Li Z, Gu B . Ubiquitin-specific peptidase USP22 negatively regulates the STAT signaling pathway by deubiquitinating SIRT1. Cell Physiol Biochem. 2014; 33(6):1863-75. DOI: 10.1159/000362964. View

Hu J, Yang D, Zhang H, Liu W, Zhao Y, Lu H . USP22 promotes tumor progression and induces epithelial-mesenchymal transition in lung adenocarcinoma. Lung Cancer. 2015; 88(3):239-45. DOI: 10.1016/j.lungcan.2015.02.019. View

Ji M, Shi H, Xie Y, Zhao Z, Li S, Chang C . Ubiquitin specific protease 22 promotes cell proliferation and tumor growth of epithelial ovarian cancer through synergy with transforming growth factor β1. Oncol Rep. 2014; 33(1):133-40. DOI: 10.3892/or.2014.3580. View

Ao N, Liu Y, Bian X, Feng H, Liu Y . Ubiquitin-specific peptidase 22 inhibits colon cancer cell invasion by suppressing the signal transducer and activator of transcription 3/matrix metalloproteinase 9 pathway. Mol Med Rep. 2015; 12(2):2107-13. DOI: 10.3892/mmr.2015.3661. View

Zhao Y, Lang G, Ito S, Bonnet J, Metzger E, Sawatsubashi S . A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell. 2008; 29(1):92-101. DOI: 10.1016/j.molcel.2007.12.011. View

Glinsky G, Berezovska O, Glinskii A . Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005; 115(6):1503-21. PMC: 1136989. DOI: 10.1172/JCI23412. View

Xu H, Liu Y, Yang Y, Dong X . Knock-down of ubiquitin-specific protease 22 by micro-RNA interference inhibits colorectal cancer growth. Int J Colorectal Dis. 2011; 27(1):21-30. DOI: 10.1007/s00384-011-1275-8. View

Wang H, Li Y, Chen J, Yuan S, Wang L, Zhang J . Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma. Tumour Biol. 2013; 34(3):1635-9. DOI: 10.1007/s13277-013-0696-0. View

Andrews L, Marciscano A, Drake C, Vignali D . LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017; 276(1):80-96. PMC: 5338468. DOI: 10.1111/imr.12519. View

10.

Li J, Wang Z, Li Y . USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2012; 138(8):1291-7. DOI: 10.1007/s00432-012-1191-5. View

11.

Ning Z, Wang A, Liang J, Xie Y, Liu J, Feng L . USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma. Int J Oncol. 2014; 45(4):1594-608. DOI: 10.3892/ijo.2014.2531. View

12.

Cao J, Yan Q . Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer. Front Oncol. 2012; 2:26. PMC: 3355875. DOI: 10.3389/fonc.2012.00026. View

13.

Schneider G, Schmidt-Supprian M, Rad R, Saur D . Tissue-specific tumorigenesis: context matters. Nat Rev Cancer. 2017; 17(4):239-253. PMC: 5823237. DOI: 10.1038/nrc.2017.5. View

14.

Ning J, Zhang J, Liu W, Lang Y, Xue Y, Xu S . Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. Eur J Histochem. 2013; 56(4):e46. PMC: 3567765. DOI: 10.4081/ejh.2012.e46. View

15.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

16.

Zhang X, Varthi M, Sykes S, Phillips C, Warzecha C, Zhu W . The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell. 2008; 29(1):102-11. PMC: 2254522. DOI: 10.1016/j.molcel.2007.12.015. View

17.

Yang M, Liu Y, Wang Y, Liu T, Ge T, Lou G . Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics. Tumour Biol. 2013; 35(2):929-34. DOI: 10.1007/s13277-013-1121-4. View

18.

Melo-Cardenas J, Zhang Y, Zhang D, Fang D . Ubiquitin-specific peptidase 22 functions and its involvement in disease. Oncotarget. 2016; 7(28):44848-44856. PMC: 5190139. DOI: 10.18632/oncotarget.8602. View

19.

Zhang X, Pfeiffer H, Thorne A, McMahon S . USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle. 2008; 7(11):1522-4. PMC: 2709765. DOI: 10.4161/cc.7.11.5962. View

20.

Glinsky G . Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin.... Cell Cycle. 2006; 5(11):1208-16. DOI: 10.4161/cc.5.11.2796. View